Radiation for Prostate Cancer, Adjusted to How Tumors Respond
Tests a 2-treatment radiation plan for prostate cancer, adjusted to each person's tumor response.
Plain-language title generated from the registry record
Registry title: Radiation Treatment of the Prostate That is Specially Adjusted for Each Person
Key facts
- Where
- Lethbridge, CanadaSee the site
- Phase
- Phase 2
Where in Canada
- Jack Ady Cancer CentreLethbridge, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AHS Cancer Control Alberta
- Trial code
- NCT07578519
- Record updated
- 3 September 2026
- Original description
A number of recent studies have successfully reduced the number of radiotherapy treatments used for prostate cancer from 39 daily treatments to as little as 5 treatments. This study is designed to determine how tumors inside the prostate respond during these 5 treatments on magnetic resonance imaging (MRI) and use that information to design 2 fraction radiotherapy treatments for prostate cancer.Read full original descriptionShow less
DOSE ADAPTED PERSONALIZED ABLATIVE RADIOTHERAPY OF THE PROSTATE
A number of recent studies have successfully reduced the number of radiotherapy treatments used for prostate cancer from 39 daily treatments to as little as 5 treatments. This study is designed to determine how tumors inside the prostate respond during these 5 treatments on magnetic resonance imaging (MRI) and use that information to design 2 fraction radiotherapy treatments for prostate cancer.
For these two fraction treatments, the first fraction of radiation will use extra radiation to any nodules in the prostate, and the second fraction of radiation will give extra radiation to the nodule(s) in the prostate based on how those nodules responded to the first fraction of radiation. This idea is a relatively old concept but has not been used in the treatment of cancer yet. This research includes a clinical trial that evaluates whether it is safe to design treatments like this.
Inclusion: Histologically confirmed adenocarcinoma of the prostate; NCCN risk grouping of intermediate or high risk prostate cancer; Patients must be 18 years of age, or older on the day of signing informed consent and be willing and able to provide written informed consent/assent; Identifiable lesion within the epithelium of the prostate as determined by the treating radiation oncologist; Have a prostate imaging reporting and data system (PIRADS) 4 or 5 nodule noted on MRI; Have not received prior pelvic radiotherapy; Life expectancy greater than 10 years; ECOG performance status <3; Eligible for SBRT to the prostate.
Exclusion: Prior trans-urethral resection of the prostate; Declined radiotherapy; Having received androgen deprivation therapy or 5-alpha reductase therapy prior to trial therapy; Has a relative contraindication to radiotherapy including systemic lupus erythematosus, TNM deficiency or scleroderma; Meeting criteria for very high-risk risk or node positive prostate cancer; Active inflammatory bowel disease; Evidence of metastatic disease on CT or bone scan; Extensive disease in the posterior prostate or aberrant anatomy that makes the safe delivery of boost irradiation not feasible; Any condition or diagnosis, that could in the opinion of the treating physician or qualified investigator interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk; No identifiable lesion within the prostate on 3T MRI; Non-adenocarcinoma histology; Unlikely to be available for all follow-up appointments; Unable to understand or sign a study consent form after use of interpreter if required; Unable to tolerate or ineligible for mpMR imaging.